Profile of Antimicrobial Consumption in Patients Assisted by a Palliative Care Team During the COVID-19 Pandemic in Brazil

Background This study aimed to evaluate the profile of antimicrobial consumption in patients assisted by a palliative care (PC) team during the COVID-19 pandemic. Methods A retrospective observational study was conducted in a quaternary hospital. Patients assisted by the PC team in 2020 were selecte...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of hospice & palliative medicine Vol. 41; no. 10; pp. 1246 - 1251
Main Authors:	Correa, Tulio L, Quitete, Matheus AC, do Nascimento, Clara RS, Carbone, Rafaela P, de Carvalho, Ricardo T, Rocha, Juraci A
Format:	Journal Article
Language:	English
Published:	Los Angeles, CA SAGE Publications 01-10-2024
Subjects:	Adult Aged Aged, 80 and over Anti-Infective Agents - therapeutic use Brazil - epidemiology COVID-19 - epidemiology Female Humans Length of Stay - statistics & numerical data Male Middle Aged Palliative Care - statistics & numerical data Retrospective Studies SARS-CoV-2 Brazil COVID-19 anti-infective agents antimicrobial agent pandemic antibiotics palliative care
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Background This study aimed to evaluate the profile of antimicrobial consumption in patients assisted by a palliative care (PC) team during the COVID-19 pandemic. Methods A retrospective observational study was conducted in a quaternary hospital. Patients assisted by the PC team in 2020 were selected. The clinical and demographic characteristics, as well as the outcomes, were assessed using electronic records. Results A total of 181 patients were included in the study, of whom 93.4% had used antimicrobials and 24.3% had had COVID-19. COVID-19 patients were more likely to receive at least one course of antimicrobial therapy. Patients who received polytherapy in the first course of treatment were more likely to die and to be still receiving antimicrobials at death. There was no significant difference in the length of hospital stay, new hospitalization in 12 months, nor the time to death among patients who received monotherapy or polytherapy during the first course of antimicrobial therapy. Conclusions There was a large amount of PC patients receiving antimicrobial therapy during the COVID-19 pandemic. SARS-CoV-2-positive patients were more likely to receive antimicrobial therapy.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	1049-9091 1938-2715 1938-2715
DOI:	10.1177/10499091231215432